China Sets Brain-Computer Interface Pricing: Invasive Procedures Priced Around RMB 6,000

Seamless integration of national drug regulation approval, medical insurance pricing and payment, and clinical application effectively avoids issues such as those related to brain-computer interfaces.Innovative HealthcareThe blank dilemma of the product "unable to charge."

China's National Healthcare Security Administration announced on April 22 that currently, most provinces in China have established government-guided pricing for brain-computer interface-related services. The cost for invasive brain-computer interface implantation is concentrated between 6,000 to 6,600 yuan per procedure, while the fitting fee for non-invasive brain-computer interfaces is around 960 yuan, effectively stabilizing market return expectations for innovative companies.

Last month, China approved the world's first invasive brain-computer interface medical device product, which has been included in the Shanghai medical insurance catalog for medical consumables, accelerating the commercialization of brain-computer interfaces. The seamless integration of national regulatory approval, medical insurance pricing, and clinical application effectively avoids the blank dilemma of "unchargeable" innovative medical products like brain-computer interfaces.

Against this backdrop, more companies are entering this field. On April 22,Lepu MedicalAt the earnings briefing, it was stated that the company's non-invasive brain-computer interface related products have already generated revenue, and the interventional multi-channel brain-computer interface product has also completed animal experiments. It has now entered the human ITT clinical research stage.

On the same day, NeuroXess, a Shanghai-based brain-computer interface company, also announced the progress of its second clinical implantation study. A high-level paraplegic patient, after receiving the implantation of a brain-computer interface device, was able to eat independently and use a brain-controlled exoskeleton to hold a pen for artistic painting.

NeuroXess stated that the most groundbreaking significance of the latest clinical implant lies in the first-time adoption of brain-computer interface-driven functional electrical stimulation technology (BCI-FES). This technology precisely captures and analyzes motor intentions in real time through cortical electrodes, bypasses the damaged spinal cord, and accurately stimulates peripheral muscles to achieve natural and coordinated finger movements. Clinical validation shows that one month post-surgery, patients have achieved precise voluntary grasping of the affected hand through thought control, allowing them to independently complete high-precision tasks such as writing and drawing, thereby restoring control to their own limbs.

From signal acquisition, intent decoding, command transmission to terminal execution, the full-link latency of the brain-computer interface device is less than 50 milliseconds, transforming thoughts into actions instantly. This indicator reaches the leading international level of latency control for implantable brain-computer interfaces.

Moreover, how to enable paralyzed individuals to walk again while simultaneously restoring the perception of walking has become one of the most focused research directions for researchers globally. A study published in the latest academic journal *Brain Stimulation* reports that an international research team has developed a "bidirectional brain-computer interface system," which has been fully tested on a patient, demonstrating a control and perception accuracy rate as high as 92%, offering promising prospects for future paraplegia treatment.New Hope。

Another major therapeutic direction for brain-computer interfaces is vision restoration. Industry participants, including tech billionaire Elon Musk's brain-computer interface company Neuralink, are attempting to restore sight to the blind through the implantation of brain-computer interfaces. Earlier this month, Mindtrix, a Chinese brain-computer interface company founded just a year and a half ago, announced that it had secured 150 million yuan in financing. The company is dedicated to the development of brain-computer interface products for visual reconstruction.

According to the "China Brain-Computer Interface Commercialization Prospective Report," since 2025, financing for brain-computer interface companies has entered a boom period. In 2025, there were approximately 25 financing events for brain-computer interfaces, with a total financing amount close to 1.45 billion yuan; in the first three months of 2026, there have already been 17 financing events for brain-computer interface companies, with the total financing amount surpassing that of the entire year of 2025.

Currently, the brain-computer interface companies in the first tier in China include BrainCo, which focuses on non-invasive technology, and invasive brain-computer interface companies such as Neuracle, StepMed, and NeuroXess. Last month, StepMed announced that it had secured 500 million yuan in strategic financing, led by Alibaba with Tencent following suit, marking the deep involvement of internet giants in the brain-computer interface sector.

Ladder Medical revealed that in early 2026, relying on the company's independently developed surgicalRobot, successfully completed the clinical implantation of the planned 256-channel wireless high-throughput invasive brain-computer interface system, and obtained effective validation of brain-controlled interaction functions.